KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Debt (2018 - 2021)

TherapeuticsMD filings provide 6 years of Non-Current Debt readings, the most recent being $171.7 million for Q3 2021.

  • On a quarterly basis, Non-Current Debt fell 27.55% to $171.7 million in Q3 2021 year-over-year; TTM through Sep 2021 was $171.7 million, a 27.55% decrease, with the full-year FY2020 number at $237.7 million, up 22.13% from a year prior.
  • Non-Current Debt hit $171.7 million in Q3 2021 for TherapeuticsMD, down from $175.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $243.8 million in Q2 2020 to a low of $73.1 million in Q2 2018.
  • Median Non-Current Debt over the past 4 years was $186.5 million (2019), compared with a mean of $168.9 million.
  • Biggest five-year swings in Non-Current Debt: soared 231.19% in 2020 and later dropped 28.11% in 2021.
  • TherapeuticsMD's Non-Current Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then fell by 27.75% to $171.7 million in 2021.
  • The last three reported values for Non-Current Debt were $171.7 million (Q3 2021), $175.3 million (Q2 2021), and $179.0 million (Q1 2021) per Business Quant data.